InMed Pharmaceuticals (INM) Capital Expenditures Growth (3y) (2022 - 2023)
InMed Pharmaceuticals (INM) Capital Expenditures Growth (3y) (2022 - 2023) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.60 Bn | 87.73 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.87 Bn | 32.13 Bn | 1.97 Bn | 6.52% |
| 3 | Zoetis | 32.75 Bn | 30.81 Bn | 1.62 Bn | 232.22% |
| 4 | Takeda Pharmaceutical | 27.63 Bn | 23.57 Bn | 4.39 Bn | 1.64% |
| 5 | United Therapeutics | 23.22 Bn | 21.07 Bn | 648.10 Mn | 75.58% |
| 6 | RedHill Biopharma | 21.80 Bn | 21.80 Bn | - | - |
| 7 | Viatris | 20.29 Bn | 18.49 Bn | 1.16 Bn | -5.84% |
| 8 | Neurocrine Biosciences | 17.84 Bn | 16.53 Bn | 800.70 Mn | 32.64% |
| 9 | Elanco Animal Health | 12.61 Bn | 12.18 Bn | 785.00 Mn | 28.56% |
| 10 | InMed Pharmaceuticals | 7.08 Mn | 1.84 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2023 | -138.83% |
| Sep 30, 2023 | -30.50% |
| Jun 30, 2023 | 466.01% |
| Sep 30, 2022 | -29.45% |